Floatz logo

Ipilimumab

Recurrent Hodgkin Lymphoma

Dana-Farber Cancer Institutemonoclonal_antibodyPhase 2Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Recurrent Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
Ibrutinib
Vanderbilt-Ingram Cancer Center
Phase 2BB
Eloxatin
OHSU Knight Cancer Institute
Phase 2B
Lipitor
Fred Hutchinson Cancer Center
Phase 2B
Yttrium Y 90 Basiliximab
City of Hope Medical Center
Phase 2CCC
HUMANIZED, DUAL-AFFINITY RE-TARGETING, OR (DART), MOLECULE THAT RECOGNIZES BOTH CD123 AND CD3
City of Hope Medical Center
Phase 2CCC

View all 15 →

Same molecule, other indications

Ipilimumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
BB
Indicative ·
69 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →